In the following video, Motley Fool health-care analyst David Williamson continues his look at the top-performing health-care stocks of last month. Here, he examines Furiex (UNKNOWN:FURX.DX), up a whopping 67% for January, most of which was made in a single day. Three important FDA approvals for type 2 diabetes drugs were granted to the Japanese drugmaker Takeda this past month, with Furiex set to receive a $25 million milestone payment from the drugs, as well as sales royalties and further potential milestone payments, which fueled investor enthusiasm over the company this past month. David tells us some of the history of Furiex, and what investors should be watching for in its pipeline.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.